Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Editas Medicine (EDIT) Common Equity (2016 - 2025)

Editas Medicine (EDIT) has disclosed Common Equity for 11 consecutive years, with $13.5 million as the latest value for Q3 2025.

  • On a quarterly basis, Common Equity fell 92.34% to $13.5 million in Q3 2025 year-over-year; TTM through Sep 2025 was $13.5 million, a 92.34% decrease, with the full-year FY2024 number at $134.3 million, down 61.54% from a year prior.
  • Common Equity was $13.5 million for Q3 2025 at Editas Medicine, down from $19.2 million in the prior quarter.
  • In the past five years, Common Equity ranged from a high of $638.0 million in Q1 2021 to a low of $13.5 million in Q3 2025.
  • A 5-year average of $342.3 million and a median of $360.5 million in 2023 define the central range for Common Equity.
  • Peak YoY movement for Common Equity: skyrocketed 171.99% in 2021, then plummeted 92.34% in 2025.
  • Editas Medicine's Common Equity stood at $553.6 million in 2021, then crashed by 34.85% to $360.7 million in 2022, then fell by 3.21% to $349.1 million in 2023, then crashed by 61.54% to $134.3 million in 2024, then plummeted by 89.98% to $13.5 million in 2025.
  • Per Business Quant, the three most recent readings for EDIT's Common Equity are $13.5 million (Q3 2025), $19.2 million (Q2 2025), and $62.4 million (Q1 2025).